Current and future treatment options in non-alcoholic steatohepatitis (NASH)

Expert Review of Gastroenterology and Hepatology

Volumn 11, Issue 4, 2017, Pages 357-369

  Lazaridis, Nikos ^a   Tsochatzis, Emmanuel ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

bariatric surgery; cirrhosis; elafibranor; fatty liver; Fibrosis; obeticholic acid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; DIGESTIVE TRACT AGENT; ELAFIBRANOR; EZETIMIBE; FARNESOID X RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; METFORMIN; OBETICHOLIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; SELONSERTIB; SIMTUZUMAB; SITAGLIPTIN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT;

ALCOHOLIC FATTY LIVER; BARIATRIC SURGERY; DIABETES MELLITUS; DIET THERAPY; DISEASE CLASSIFICATION; DRUG EFFICACY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REVIEW; TREATMENT RESPONSE; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; COMPLICATION; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-OBESITY AGENTS; BARIATRIC SURGERY; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 85014888346     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2017.1293523     Document Type: Review

References (127)

1. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy:a prospective study. Gastroenterology. 2011;140:124–131.
2. Chalasani N, Younossi Z, Lavine JE, et al.; American Association for the Study of Liver D, American College of G, American Gastroenterological A. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811–826.
3. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.•• The European Association for the Study of the Liver (EASL) guidelines for an updated management of nonalcoholic fatty liver disease.
4. Adiels M, Taskinen MR, Boren J., Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep. 2008;8:60–64.
5. Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population:the Rotterdam study. Hepatology. 2016;63:138–147.
6. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–1048.• Comprehensive review on the pathogenesis of NAFLD and NASH.
7. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42:563–570.
8. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.
9. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–140.
10. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009;58:1281–1288.
11. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.
12. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.
13. Ratziu V, Harrison SA, Francque S, et al.; Group G-IS. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147–59 e5.• The first RCT study with elafibranor in NASH patients failed to achieve the primary outcome of reversal of NASH.
14. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–690.• Liraglutide can ameliorate liver histology in NASH patients compared with placebo and reduce body weight at the same time.
15. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.•• The first large RCT assessing the beneficial role of obeticholic acid in NASH patients.
16. Sanyal AJ, Abdelmalek MF, Suzuki A, et al.; Group E-AS. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147:377-84.e1.
17. Wong VW, Wong GL, Chan AW, et al. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria:a randomized trial. J Gastroenterol Hepatol. 2013;28:57–62.
18. Torres DM, Jones FJ, Shaw JC, et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans:a 12-month randomized, prospective, open- label trial. Hepatology. 2011;54:1631–1639.
19. Lavine JE, Schwimmer JB, van Natta ML, et al.; Nonalcoholic Steatohepatitis Clinical Research N. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:the TONIC randomized controlled trial. JAMA. 2011;305:1659–1668.• Metformin did not significantly improve liver histology in children and adolescents with NAFLD and NASH.
20. Malaguarnera M, Gargante MP, Russo C, et al. L-carnitine supplementation to diet:a new tool in treatment of nonalcoholic steatohepatitis–a randomized and controlled clinical trial. Am J Gastroenterol. 2010;105:1338–1345.
21. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.• An RCT investigating the role of pioglitazone and vitamin E in NASH.
22. Leuschner UF, Lindenthal B, Herrmann G, et al.; Group NS. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis:a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472–479.
23. Vilar Gomez E, Rodriguez de Miranda A, Gra Oramas B, et al. Clinical trial:a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2009;30:999–1009.
24. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176–1184.
25. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis:one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology. 2008;135:100–110.
26. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis:results of a randomized trial. Hepatology. 2004;39:770–778.
27. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut. 2007;56:1760–1769.
28. Zein CO, Unalp A, Colvin R, et al.; Nonalcoholic Steatohepatitis Clinical Research N. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54:753–759.
29. Tsochatzis EA, Papatheodoridis GV. Smoking is associated with histological severity in nonalcoholic steatohepatitis. Hepatology. 2010;52:1522–1523.
30. Sookoian S, Castano GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease:a meta-analysis of 43 175 individuals. Gut. 2014;63:530–532.
31. Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57:384–391.
32. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med. 1970;282:829–834.
33. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408–1413.
34. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53:413–419.
35. Phelan S, Wadden TA, Berkowitz RI, et al. Impact of weight loss on the metabolic syndrome. Int J Obes. 2007;31:1442–1448.
36. Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis:a randomized, prospective trial. Hepatology. 2009;49:80–86.
37. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of >/= 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024–1030.
38. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–5.• A study that demonstrates the importance of weight loss for the improvement of hepatic histology.
39. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107.
40. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis:a pilot study. Am J Gastroenterol. 2005;100:1072–1081.
41. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD):a population based study. J Hepatol. 2007;47:711–717.
42. Abdelmalek MF, Suzuki A, Guy C, et al.; Nonalcoholic Steatohepatitis Clinical Research N. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971.
43. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53:1504–1514.
44. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–143.
45. Goodpaster BH, Delany JP, Otto AD, et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults:a randomized trial. JAMA. 2010;304:1795–1802.
46. Church TS, Kuk JL, Ross R, et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006;130:2023–2030.
47. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105–1112.
48. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283.
49. Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease:a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.
50. Keating SE, Hackett DA, Parker HM, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63:174–182.
51. Harrison SA, Ramrakhiani S, Brunt EM, et al. Orlistat in the treatment of NASH:a case series. Am J Gastroenterol. 2003;98:926–930.
52. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:639–644.
53. Haines NW, Baker AL, Boyer JL, et al. Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity:a prospective study. Hepatology. 1981;1:161–167.
54. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007340. doi:10.1002/14651858.CD007340.pub2.
55. Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology. 2016;63:1026–1040.
56. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease:improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647–1654.
57. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–540.
58. Taitano AA, Markow M, Finan JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19:429–7.
59. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–6.
60. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:1082–1090.
61. Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH):a pilot trial. Therap Adv Gastroenterol. 2009;2:157–163.
62. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner:population-based and in vitro studies. Gut. 2013;62:606–615.
63. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis:results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010;51:445–453.
64. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
65. Home PD, Pocock SJ, Beck-Nielsen H, et al.; Team RS. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD):a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–2135.
66. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188–196.
67. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46:424–429.
68. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307.
69. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus:a meta-analysis of randomized trials. JAMA. 2007;298:1180–1188.
70. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones:a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–1136.
71. Shah P, Mudaliar S. Pioglitazone:side effect and safety profile. Expert Opin Drug Saf. 2010;9:347–354.
72. Jb B, Rosenstock J, Sesti G, et al.; Group L-S. Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
73. Astrup A, Rossner S, van Gaal L, et al.; Group NNS. Effects of liraglutide in the treatment of obesity:a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616.
74. Kim JH, Hong HN, Choi HH, et al. YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models. Hepatology. 2016;64:1136A–7A.
75. Trevaskis J, Beaton ML, Bednarek M, et al. The dual glucagon-like peptide-1 (GLP-1)/Glucagon receptor agonist MEDI0382 improves metabolic and hepatic indices of NASH in mice. Hepatology. 2016;64:751A.
76. Yamamoto T, Nakade Y, Yamauchi T, et al. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J Gastroenterol. 2016;22:2512–2523.
77. Jung YA, Choi YK, Jung GS, et al. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract. 2014;105:47–57.
78. Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75:240–244.
79. Cui J, Philo L, Nguyen P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease:a randomized controlled trial. J Hepatol. 2016;65:369–376.
80. Athyros VG, Tziomalos K, Gossios TD, et al.; Group GSC. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study:a post-hoc analysis. Lancet. 2010;376:1916–1922.
81. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis:a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994.
82. Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia:an open-label, pilot study. Hepatol Res. 2011;41:1057–1065.
83. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21:7860–7868.
84. Simon TG, Bonilla H, Yan P, et al. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV results from ERCHIVES. Hepatology. 2016;64:47–57.
85. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601–1608.
86. Loomba R, Sirlin CB, Ang B, et al.; San Diego Integrated NRC. Ezetimibe for the treatment of nonalcoholic steatohepatitis:assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239–1250.
87. Di Minno MN, Russolillo A, Lupoli R, et al. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18:5839–5847.
88. Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015;49:137–144.
89. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485–2490.
90. Kawanaka M, Nishino K, Nakamura J, et al. Treatment of nonalcoholic steatohepatitis with vitamins E and C:a pilot study. Hepat Med. 2013;5:11–16.
91. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107–1115.
92. Han Y, Shi JP, Ma AL, et al. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig. 2014;34:1–7.
93. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention:systematic review and meta-analysis. JAMA. 2007;297:842–857.
94. Klein EA, Thompson IM, Jr., Tangen CM, et al. Vitamin E and the risk of prostate cancer:the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549–1556.
95. Schurks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes:meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702.
96. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191.
97. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-82.e1.
98. Traussnigg S, Kienbacher C, Halilbasic E, et al. Efficacy and safety of the non-steroidal farnesoid X receptor agonist PX-104 in patients with non-alcoholic fatty liver disease (NAFLD). Hepatology. 2016;64:536A–7A.
99. Djedjos CS, Kirby B, Billin A, et al. Pharmacodynamic effects of the oral, non-steroidal farnesoid X receptor agonist GS-9674 in healthy volunteers. Hepatology. 2016;64:543A.
100. Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care. 2011;34:2008–2014.
101. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013;36:2923–2930.
102. Francque S, Verrijken A, Caron S, et al. PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol. 2015;63:164–173.
103. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–1952.
104. Loomba R, Lawitz E, Mantry PS, et al. GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH):a randomized, phase 2 trial. Hepatology. 2016;64:1119A–20A.
105. Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis:emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249–274.•• A recent review about new compounds and molecules for NASH treatment based on the different pathogenic pathways.
106. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180–190. doi:10.1136/gutjnl-2016-312431.
107. Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085–91 e1.
108. Rodriguez-Ramiro I, Vauzour D, Minihane AM. Polyphenols and non-alcoholic fatty liver disease:impact and mechanisms. Proc Nutr Soc. 2016;75:47–60.
109. Loffredo L, Del Ben M, Perri L, et al. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016;44:279–286.
110. Koukias N, Buzzetti E, Tsochatzis EA. Intestinal hormones, gut microbiota and nonalcoholic fatty liver disease (NAFLD). Minerva Endocrinol. 2016 Nov 23. [Epub ahead of print]. PMID:27879962.
111. Wong VW, Won GL, Chim AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12:256–262.
112. Rysz J, Gluba-Brzozka A, Mikhailidis DP, et al. Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. Expert Opin Investig Drugs. 2015;24:603–610.
113. Saboo B, Prajapati A, Joshi S, et al. To assess the effect of 4mg saroglitazar on patients of diabetes dyslipidemia with nonalcoholic fatty liver disease for 24 weeks at diabetes care centre (712-P-2015). Available from: https://ada.scientificposters.com/epsAbstractADA.cfm?id=1:American Diabetes Association [online]; 2015.
114. Joshi S, Ghosh S, Shah P, et al. Saroglitazar in diabetic dyslipidemia:1 year data. (126-LB-2015). Available from: https://ada.scientificposters.com/epsAbstractADA.cfm?id=1:American Diabetes Association [online]; 2015.
115. Sanyal AJ, Cusi K, Patel S, et al. Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on liver fat content in nonalcoholic fatty liver disease. Hepatology. 2015;62:1253A.
116. Ratziu V, Bedossa P, Francque SM, et al. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014;12:1724-30.e5.
117. Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–966.
118. Shiffman M, Freilich B, Vuppalanchi R, et al. A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases (LP37). J Hepatology. 2015;62:S282.
119. Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:CENTAUR phase 2b study design. Contemp Clin Trials. 2016;47:356–365.
120. Sanyal AJ, Ratziu V, Harrison S, et al. Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis:results from the year 1 primary analysis of the phase 2b CENTAUR study. Hepatology. 2016;64:1118A–9A.
121. Lalazar G, Mizrahi M, Turgeman I, et al. Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell Induction, and alleviates insulin resistance:results of a phase IIa blinded placebo-controlled trial. J Clin Immunol. 2015;35:399–407.
122. Sanyal AJ, Miller V. Regulatory science and drug approval for alcoholic and nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1723–1727.• Recent developments in the principles of drug approval for NASH through surrogate end points.
123. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602.• Patients with NASH exhibit increased mortality compared with the general population in Sweden.
124. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554.
125. Tsochatzis E, Bruno S, Isgro G, et al. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol. 2014;60:948–954.
126. Manousou P, Dhillon AP, Isgro G, et al. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl. 2011;17:178–188.
127. Calvaruso V, Dhillon AP, Tsochatzis E, et al. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. J Gastroenterol Hepatol. 2012;27:1227–1232.